Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: J Stroke Cerebrovasc Dis. 2022 Aug 30;31(10):106724. doi: 10.1016/j.jstrokecerebrovasdis.2022.106724

Figure 2.

Figure 2.

a) Representative EMG trace of participant in Cyproheptadine group who showed a decrease in grip termination time from baseline (top) to week 1 (bottom). The shaded green area denotes the instructed MVC activation time, as prompted by an auditory cue from a computer, while the shaded gray bar indi-cates the time for EMG activity to return to baseline (EMG amplitude within ยง 3SDs of baseline resting amplitude) the grip termination time. b) Grip termi-nation time over the course of the study for the group receiving cyproheptadine (light) and the group receiving matching pills of placebo (dark). c) Grip termination times vs. week for participants in CMSA-H 2 (left) and CMSA-H 3 (right) - cyproheptadine (light), placebo (dark). Only participants taking the listed doses are included in the plots. Error bars indicate standard error.